Inozyme Pharma (INZY) Competitors $0.92 -0.04 (-4.40%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.95 +0.03 (+2.99%) As of 04/17/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INZY vs. MBX, CADL, ZYBT, ACB, ATXS, CMPX, DRUG, MNPR, NVCT, and LFCRShould you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include MBX Biosciences (MBX), Candel Therapeutics (CADL), Zhengye Biotechnology (ZYBT), Aurora Cannabis (ACB), Astria Therapeutics (ATXS), Compass Therapeutics (CMPX), Bright Minds Biosciences (DRUG), Monopar Therapeutics (MNPR), Nuvectis Pharma (NVCT), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. Inozyme Pharma vs. MBX Biosciences Candel Therapeutics Zhengye Biotechnology Aurora Cannabis Astria Therapeutics Compass Therapeutics Bright Minds Biosciences Monopar Therapeutics Nuvectis Pharma Lifecore Biomedical Inozyme Pharma (NASDAQ:INZY) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends. Does the MarketBeat Community favor INZY or MBX? Inozyme Pharma received 55 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 88.57% of users gave Inozyme Pharma an outperform vote. CompanyUnderperformOutperformInozyme PharmaOutperform Votes6288.57% Underperform Votes811.43%MBX BiosciencesOutperform Votes7100.00% Underperform VotesNo Votes Which has preferable earnings and valuation, INZY or MBX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInozyme PharmaN/AN/A-$71.17M-$1.63-0.56MBX BiosciencesN/AN/AN/AN/AN/A Does the media favor INZY or MBX? In the previous week, MBX Biosciences had 1 more articles in the media than Inozyme Pharma. MarketBeat recorded 2 mentions for MBX Biosciences and 1 mentions for Inozyme Pharma. Inozyme Pharma's average media sentiment score of 0.89 beat MBX Biosciences' score of 0.81 indicating that Inozyme Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inozyme Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend INZY or MBX? Inozyme Pharma presently has a consensus target price of $14.63, suggesting a potential upside of 1,490.54%. MBX Biosciences has a consensus target price of $37.50, suggesting a potential upside of 392.13%. Given Inozyme Pharma's higher probable upside, research analysts plainly believe Inozyme Pharma is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inozyme Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of INZY or MBX? 88.3% of Inozyme Pharma shares are held by institutional investors. 11.2% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is INZY or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Inozyme Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Inozyme PharmaN/A -88.42% -57.02% MBX Biosciences N/A N/A N/A SummaryInozyme Pharma beats MBX Biosciences on 6 of the 10 factors compared between the two stocks. Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INZY vs. The Competition Export to ExcelMetricInozyme PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.07M$6.44B$5.30B$7.35BDividend YieldN/A3.20%5.45%4.30%P/E Ratio-0.596.8921.8617.81Price / SalesN/A230.51380.6697.70Price / CashN/A65.6738.2634.64Price / Book0.415.936.453.98Net Income-$71.17M$142.99M$3.22B$247.81M1 Month Performance-7.94%-13.56%-9.76%-7.94%1 Year Performance-79.61%-8.89%11.49%1.52% Inozyme Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INZYInozyme Pharma2.8952 of 5 stars$0.92-4.4%$14.63+1,490.5%-79.9%$59.07MN/A-0.5950News CoverageMBXMBX Biosciences2.2157 of 5 stars$7.43+0.3%$37.50+404.7%N/A$248.34MN/A0.0036Gap UpCADLCandel Therapeutics2.2769 of 5 stars$5.17+4.0%$21.00+306.2%-16.3%$244.21M$120,000.00-2.9960Short Interest ↑ZYBTZhengye BiotechnologyN/A$5.12+26.1%N/AN/A$241.49M$189.75M0.00278Gap UpHigh Trading VolumeACBAurora Cannabis0.4188 of 5 stars$4.25-0.7%N/A-32.1%$238.91M$320.81M85.021,340ATXSAstria Therapeutics1.7672 of 5 stars$4.22+4.5%$26.60+530.3%-61.7%$238.15MN/A-2.0230Gap DownCMPXCompass Therapeutics3.2242 of 5 stars$1.72+1.5%$13.38+677.6%+17.4%$237.85M$850,000.00-4.6520Short Interest ↑Gap DownDRUGBright Minds Biosciences3.0098 of 5 stars$32.75+13.6%$84.33+157.5%+2,705.9%$230.69MN/A-192.64N/ANews CoverageGap UpMNPRMonopar Therapeutics1.7799 of 5 stars$37.49+7.5%$55.33+47.6%+1,067.8%$229.18MN/A-19.0310Gap UpNVCTNuvectis Pharma2.0744 of 5 stars$9.78+17.7%$15.67+60.2%+31.8%$228.77MN/A-8.438Positive NewsGap UpLFCRLifecore Biomedical1.161 of 5 stars$6.17+6.0%$8.00+29.7%+1.5%$228.44M$130.86M-11.02690News Coverage Related Companies and Tools Related Companies MBX Biosciences Alternatives Candel Therapeutics Alternatives Zhengye Biotechnology Alternatives Aurora Cannabis Alternatives Astria Therapeutics Alternatives Compass Therapeutics Alternatives Bright Minds Biosciences Alternatives Monopar Therapeutics Alternatives Nuvectis Pharma Alternatives Lifecore Biomedical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INZY) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
